PT - JOURNAL ARTICLE AU - Alsentzer, Emily AU - Rasmussen, Matthew J AU - Fontoura, Romy AU - Cull, Alexis L AU - Beaulieu-Jones, Brett AU - Gray, Kathryn J AU - Bates, David W AU - Kovacheva, Vesela P TI - Zero-shot Interpretable Phenotyping of Postpartum Hemorrhage Using Large Language Models AID - 10.1101/2023.05.31.23290753 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.31.23290753 4099 - http://medrxiv.org/content/early/2023/06/01/2023.05.31.23290753.short 4100 - http://medrxiv.org/content/early/2023/06/01/2023.05.31.23290753.full AB - Many areas of medicine would benefit from deeper, more accurate phenotyping, but there are limited approaches for phenotyping using clinical notes without substantial annotated data. Large language models (LLMs) have demonstrated immense potential to adapt to novel tasks with no additional training by specifying task-specific i nstructions. We investigated the per-formance of a publicly available LLM, Flan-T5, in phenotyping patients with postpartum hemorrhage (PPH) using discharge notes from electronic health records (n=271,081). The language model achieved strong performance in extracting 24 granular concepts associated with PPH. Identifying these granular concepts accurately allowed the development of inter-pretable, complex phenotypes and subtypes. The Flan-T5 model achieved high fidelity in phenotyping PPH (positive predictive value of 0.95), identifying 47% more patients with this complication compared to the current standard of using claims codes. This LLM pipeline can be used reliably for subtyping PPH and outperformed a claims-based approach on the three most common PPH subtypes associated with uterine atony, abnormal placentation, and obstetric trauma. The advantage of this approach to subtyping is its interpretability, as each concept contributing to the subtype determination can be evaluated. Moreover, as definitions may change over time due to new guidelines, using granular concepts to create complex phenotypes enables prompt and efficient updating of the algorithm. Using this lan-guage modelling approach enables rapid phenotyping without the need for any manually annotated training data across multiple clinical use cases.Competing Interest StatementKJG has served as a consultant to Illumina Inc., Aetion, Roche, and BillionToOne outside the scope of the submitted work. DWB reports grants and personal fees from EarlySense, personal fees from CDI Negev, equity from Valera Health, equity from CLEW, equity from MDClone, personal fees and equity from AESOP Technology, personal fees and equity from FeelBetter, and grants from IBM Watson Health, outside the submitted work. VPK reports consulting fees from Avania CRO unrelated to the current work.Funding StatementKJG reports funding from NIH/NHLBI grants K08 HL146963-02, K08 HL146963-02S1, and R03 HL162756. VPK reports funding from the NIH/NHLBI grants 1K08HL161326-01A1, Anesthesia Patient Safety Foundation (APSF), and the BWH IGNITE Award. The funders played no role in study design, data collection, analysis and interpretation of data, or the writing of this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Mass General Brigham Institutional Review Board, protocol #2020P002859, with a waiver of patient consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe patient data used in this study contains identifiable protected health information and therefore cannot be shared publicly. Mass General Brigham investigators with an appropriate IRB approval can contact the authors directly regarding data access.